EUCTR2007-002605-53-ES进行中（未招募）不适用
Antagonistas aldosterónicos en el tratamiento de pacientes con ventrículo derecho sistémico: ensayo clínico aleatorizado. - EVEDES STUDY.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau0 个研究点开始时间: 2008年4月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult patients (>18 years).
- •Diagnosis of transposition of the great arteries corrected by means of atrial switch procedures (Senning or Mustard procedures).
- •Regular follow-up at a tertiary referral center.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concomitant disease with life expectancy<1 year.
- •Inclusion in heart transplant waiting list.
- •Basal seric creatinine level>1.5mg/dl.
- •Basal seric potassium level>5.0mmol/L.
- •Intolerance to the investigational medical product.
- •Treatment with spironolactone or eplerenone within the previous 6 months.
- •Inability to undergo cardiac magnetic ressonance.
- •Pregnancy or breast feeding.
- •Denial of informed consent.
研究者
相似试验
进行中（未招募）
不适用
Aldosterone receptor blockade in patients with chronic kidney disease.Influence on arterial stiffness and kidney function. - ALBLOCK-2Chronic kidney disease, stages 3 and 4.MedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2009-012445-35-DKHerlev Hospital80
进行中（未招募）
不适用
Blocage des effets létaux de l'aldostérone dans l'infarctus du myocarde traité ou non par la reperfusion pour améliorer le pronostic et la survie à six mois : Etude randomisée comparant un blocage spécifique de l'aldostérone en plus du traitement usuel au traitement usuel seul débuté dans les 72 premières heures après la survenue d'un infarctus aigu du myocardeALBATROSS - ALBATROSSInfractusMedDRA version: 8.1Level: PTClassification code 10000891Term: IMCEUCTR2008-006857-42-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
进行中（未招募）
不适用
Establishing the benefits of a tablet commonly used to treat raised blood pressure in people with Chronic Kidney Disease stage 3b.We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate markers for vascular disease in people with stage 3b (eGFR 30-44 ml/min/1.73m2)Chronic Kidney Disease.MedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 15.1Level: PTClassification code 10018355Term: Glomerular filtration rateSystem Organ Class: 10022891 - InvestigationsMedDRA version: 15.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2012-002672-13-GBniversity of Oxford, Clinical Trials and Research Governance Office2,616
进行中（未招募）
1 期
ALdosterone antagonist Chronic HEModialysis Interventional Survival Trialend-stage renal failure (ESRF)cardiovascular complicationMedDRA version: 20.0Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersMedDRA version: 20.0Level: LLTClassification code 10050441Term: Chronic renal insufficiencySystem Organ Class: 100000004857EUCTR2012-002856-18-BECHRU de Brest825
进行中（未招募）
不适用
ALdosterone antagonist Chronic HEModialysis Interventional Survival TrialEUCTR2012-002856-18-FRCHRU de Brest